Begin main content

Drug Reimbursement Recommendation - inotersen (Tegsedi)

December 20, 2019
Today, CADTH has issued final recommendations for: inotersen (Tegsedi) Indications: hereditary transthyretin amyloidosis Recommendation: Reimburse with clinical criteria and/or conditions For more information

Patient Input and Clinical Experts: Duobrii

December 19, 2019
CADTH has received the following notice(s) of pending drug submission(s). Brand name Halobetasol propionate and tazarotene Generic name Duobrii Manufacturer Bausch Health, Canada Inc. Indication(s) Psoriasis, moderate to severe plaque Project Number SR0638-000 Call for patient...

New at CADTH — December 2019

December 9, 2019
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

Drug Reimbursement Recommendation - Nerlynx, Tecentriq and Lynparza

December 5, 2019
Today, CADTH has issued final recommendations for: Nerlynx for Hormone Receptor-Positive Breast Cancer Funding Request: For patients with HER2-positive, hormone receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months. Recommendation: Do not reimburse Notification to implemen...

Drug Reimbursement Recommendation - lanadelumab (Takhzyro) + certolizumab pegol (Cimzia)

November 22, 2019
Today, CADTH has issued final recommendations for: lanadelumab (Takhzyro) Indications: Hereditary angioedema, prevention Recommendation: Reimburse with clinical criteria and/or conditions For more information certolizumab pegol (Cimzia) Indications: Psoriasis, moderate to severe plaque Recommendation: Reimburse with clinical criteria and/...